MedPath
HSA Approval

BANEOCIN POWDER

SIN00678P

BANEOCIN POWDER

BANEOCIN POWDER

May 3, 1988

NOVARTIS (SINGAPORE) PTE LTD

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

POWDER

TOPICAL

Medical Information

D06AX04

neomycin

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

PHARMAZEUTISCHE FABRIK MONTAVIT GMBH

Active Ingredients

BACITRACIN ZINC

250 iu/g

Bacitracin

NEOMYCIN SULPHATE EQV NEOMYCIN

5000 iu/g

Neomycin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BANEOCIN POWDER - HSA Approval | MedPath